Con: Antifibrinolytics Should Not Be Used Routinely in Low-Risk Cardiac Surgery

J Cardiothorac Vasc Anesth. 2016 Jan;30(1):248-51. doi: 10.1053/j.jvca.2015.08.013. Epub 2015 Aug 20.

Authors

Reed Harvey¹, Ali Salehi²

Affiliations

¹ David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA. Electronic address: rharvey@mednet.ucla.edu.
² David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.

PMID: 26613643
DOI: 10.1053/j.jvca.2015.08.013

No abstract available

Keywords: antifibrinolytics; cardiothoracic surgery; epsilon-aminocaproic acid; red blood cell transfusion; tranexamic acid.

Publication types

Review

MeSH terms

Aminocaproic Acid / adverse effects
Aminocaproic Acid / therapeutic use
Antifibrinolytic Agents / adverse effects*
Antifibrinolytic Agents / therapeutic use
Cardiac Surgical Procedures / adverse effects*
Cardiac Surgical Procedures / methods
Humans
Intraoperative Complications / chemically induced*
Intraoperative Complications / drug therapy
Intraoperative Complications / etiology
Risk Factors
Tranexamic Acid / adverse effects
Tranexamic Acid / therapeutic use

Substances

Antifibrinolytic Agents
Tranexamic Acid
Aminocaproic Acid